HEPS vs MLKN

The company exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While revenue growth remains strong at 36.9% YoY, this has failed to translate into profitability, as evidenced by a catastrophic ROE of -213.73% and a consistent track record of missing earnings estimates. Liquidity is a primary concern with a Quick Ratio of 0.59 and a Current Ratio below 1.0, suggesting an inability to meet short-term obligations. Despite a positive analyst target price, the deterministic data points to a high-risk profile with significant insolvency concerns.

MLKN exhibits a fragile financial profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a current price ($15.62) that significantly exceeds both its Graham Number ($8.12) and Intrinsic Value ($1.05). While forward valuation metrics (Forward P/E 7.82, PEG 0.65) suggest potential upside, these are overshadowed by a catastrophic dividend payout ratio of 500%, indicating the current yield is unsustainable. The technical trend is completely bearish (0/100), and long-term price performance is severely depressed (-59% over 5 years).